Invention Grant
- Patent Title: Chimeric antigen receptor-modified NK-92 cells
-
Application No.: US17812264Application Date: 2022-07-13
-
Publication No.: US12109238B2Publication Date: 2024-10-08
- Inventor: Laurent H. Boissel , Hans G. Klingemann
- Applicant: ImmunityBio, Inc.
- Applicant Address: US CA Culver City
- Assignee: ImmunityBio, Inc.
- Current Assignee: ImmunityBio, Inc.
- Current Assignee Address: US CA Culver City
- Agency: Umberg Zipser LLP
- Agent Martin Fessenmaier
- Main IPC: A61K35/17
- IPC: A61K35/17 ; A61K35/28 ; A61K39/395 ; A61K45/06 ; A61P35/00 ; C07K14/705 ; C07K14/735 ; C07K16/10 ; C07K16/28 ; C07K16/32 ; C12N5/0783
Abstract:
Provided are NK-92 cells expressing a chimeric antigen receptor (CAR). The CAR can comprise an intracellular domain of FcεRIγ. Also described are methods for treating a patient having or suspected of having a disease that is treatable with NK-92 cells, such as cancer or a viral infection, comprising administering to the patient NK-92-CAR cells.
Public/Granted literature
- US20240238623A9 Chimeric Antigen Receptor-Modified NK-92 Cells Public/Granted day:2024-07-18
Information query
IPC分类:
